Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Biofrontera Revenue Rises 30% to $9.1 Million in Third Quarter

None

Biofrontera (NASDAQ: BFRI) reported third-quarter 2026 net product revenue of $9.1 million, up 29.8% from $7.0 million a year earlier. The company recorded a net loss of $6.4 million, or $0.42 per share, compared with a $6.6 million loss, or $0.62 per share, in the prior-year quarter.

Gross margin rose to 74.4% from 70.7%. For the first nine months of 2026, net product revenue was $31.2 million, up 26.6%, while net loss narrowed to $11.8 million from $16.2 million.

  • Third-quarter net product revenue was $9.07 million on the condensed consolidated statements of operations.
  • FDA approved Ameluz PDT for superficial basal cell carcinoma on September 9, 2026.
  • U.S. Customs and Border Protection ruled the redesigned RhodoLED XL-C lamp was not subject to the ITC exclusion order.
  • Cash and cash equivalents were $3.2 million as of September 30, 2026, versus $6.4 million at December 31, 2025.
  • Adjusted EBITDA, a non-GAAP measure, was negative $5.5 million, compared with negative $6.0 million a year earlier.
EARLY ACCESS
Receive BFRIW Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

$BFRIW Hedge Fund Activity

We have seen 1 institutional investors add shares of $BFRIW stock to their portfolio, and 1 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles